Last updated on May 2018

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC


Brief description of study

The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.

Detailed Study Description

Objective: The primary objective of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy. Study site(s) and number of patients planned: Approximately 1500 patients will be recruited in Europe. The recruitment will be increased beyond that as the study will expand in other regions of the world (America, Asia). Study Design This will be an open-label, single-arm, multinational, multicenter, real world treatment study. Target patient population: Adult patients (fulfilling the definition of "age of majority" per local regulations) with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC with confirmed T790M mutation, who have received prior EGFR-TKI therapy. Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day. Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria). The study will be closed in each participating country as soon as possible following national reimbursement of AZD9291 in that country (up to a max of 90 days post reimbursement). Enrolment will be closed within 6 months after market license approval in that country or at national reimbursement, whichever is sooner. Patients withdrawing from the treatment prior to national reimbursement will be followed up as part of this study. Patients on treatment will receive commercial supply until documented disease progression as per investigator assessment. In the event that national reimbursement should not be granted following a reasonable time after market license approval in the country, the study will be closed in a maximum period of 18 months after the last patient is enrolled in that country. If applicable, timelines for conversion to commercial drug will be agreed with local bodies which may include regulatory agencies, ethics committees, and institutions. Patient will be followed until death or lost to follow-up. Study measures: Data collected will include patient demographics, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutational status), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS), and safety (including serious adverse events [SAEs], adverse events leading to dose modification, and adverse events of special interest [interstitial lung disease/pneumonitis-like events, and QTc prolongation events]). Statistical methods: All data will be presented for the overall full analysis/evaluable set, and also by cohorts defined by number and type of previous treatment lines for the advanced disease. Descriptive statistics will be used for all variables, as appropriate. Continuous variables will be summarised by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarised by frequency counts and percentages for each category. OS and PFS will be summarized using Kaplan-Meier estimates of the median time to death or censoring and quartiles together with their 95% confidence intervals.

Clinical Study Identifier: NCT02474355

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Buenos Aires, Argentina

AstraZeneca Clinical Study Information Center

Research Site
Caba, Argentina

AstraZeneca Clinical Study Information Center

Research Site
Cordoba, Argentina

AstraZeneca Clinical Study Information Center

Research Site
La Rioja, Argentina

AstraZeneca Clinical Study Information Center

Research Site
Bedford Park, Australia

AstraZeneca Clinical Study Information Center

Research Site
Douglas, Australia

AstraZeneca Clinical Study Information Center

Research Site
Kurralta Park, Australia

AstraZeneca Clinical Study Information Center

Research Site
Melbourne, Australia

AstraZeneca Clinical Study Information Center

Research Site
Randwick, Australia

AstraZeneca Clinical Study Information Center

Research Site
Waratah, Australia

AstraZeneca Clinical Study Information Center

Research Site
Innsbruck, Austria

AstraZeneca Clinical Study Information Center

Research Site
Linz, Austria

AstraZeneca Clinical Study Information Center

Research Site
Salzburg, Austria

AstraZeneca Clinical Study Information Center

Research Site
Wien, Austria

AstraZeneca Clinical Study Information Center

Research Site
Charleroi, Belgium

AstraZeneca Clinical Study Information Center

Research Site
Edegem, Belgium

AstraZeneca Clinical Study Information Center

Research Site
Leuven, Belgium

AstraZeneca Clinical Study Information Center

Research Site
Barretos, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Belo Horizonte, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Florianópolis, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Ijuí, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Itajai, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Porto Alegre, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Rio de Janeiro, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Salvador, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Sao Paulo, Brazil

AstraZeneca Clinical Study Information Center

Research Site
São Paulo, Brazil

AstraZeneca Clinical Study Information Center

Research Site
Calgary, AB Canada

AstraZeneca Clinical Study Information Center

Research Site
Burnaby, BC Canada

AstraZeneca Clinical Study Information Center

Research Site
Vancouver, BC Canada

AstraZeneca Clinical Study Information Center

Research Site
Hamilton, ON Canada

AstraZeneca Clinical Study Information Center

Research Site
North York, ON Canada

AstraZeneca Clinical Study Information Center

Research Site
Oshawa, ON Canada

AstraZeneca Clinical Study Information Center

Research Site
Toronto, ON Canada

AstraZeneca Clinical Study Information Center

Research Site
Montreal, QC Canada

AstraZeneca Clinical Study Information Center

Research Site
Quebec, QC Canada

AstraZeneca Clinical Study Information Center

Research Site
Regina, Saskatchewan, Canada

AstraZeneca Clinical Study Information Center

Research Site
Beijing, China

AstraZeneca Clinical Study Information Center

Research Site
Changchun, China

AstraZeneca Clinical Study Information Center

Research Site
Changsha, China

AstraZeneca Clinical Study Information Center

Research Site
Chengdu, China

AstraZeneca Clinical Study Information Center

Research Site
Chongqing, China

AstraZeneca Clinical Study Information Center

Research Site
ChongQing, China

AstraZeneca Clinical Study Information Center

Research Site
Chongqin, China

AstraZeneca Clinical Study Information Center

Research Site
Dalian, China

AstraZeneca Clinical Study Information Center

Research Site
Fuzhou, China

AstraZeneca Clinical Study Information Center

Research Site
Guangzhou, China

AstraZeneca Clinical Study Information Center

Research Site
GuangZhou, China

AstraZeneca Clinical Study Information Center

Research Site
Haikou, China

AstraZeneca Clinical Study Information Center

Research Site
Hangzhou, China

AstraZeneca Clinical Study Information Center

Research Site
Harbin, China

AstraZeneca Clinical Study Information Center

Research Site
Hohhot, China

AstraZeneca Clinical Study Information Center

Research Site
Ji Nan, China

AstraZeneca Clinical Study Information Center

Research Site
Kunming, China

AstraZeneca Clinical Study Information Center

Research Site
Linhai, China

AstraZeneca Clinical Study Information Center

Research Site
Nanchang, China

AstraZeneca Clinical Study Information Center

Research Site
Nanjing, China

AstraZeneca Clinical Study Information Center

Research Site
Nanning, China

AstraZeneca Clinical Study Information Center

Research Site
Nantong, China

AstraZeneca Clinical Study Information Center

Research Site
Qingdao, China

AstraZeneca Clinical Study Information Center

Research Site
Shanghai, China

AstraZeneca Clinical Study Information Center

Research Site
Shenyang, China

AstraZeneca Clinical Study Information Center

Research Site
Shenzhen, China

AstraZeneca Clinical Study Information Center

Research Site
Shijiahzhuang, China

AstraZeneca Clinical Study Information Center

Research Site
Tianjin, China

AstraZeneca Clinical Study Information Center

Research Site
Urumqi, China

AstraZeneca Clinical Study Information Center

Research Site
Xuzhou, China

AstraZeneca Clinical Study Information Center

Research Site
Yancheng, China

AstraZeneca Clinical Study Information Center

Research Site
Yangzhou, China

AstraZeneca Clinical Study Information Center

Research Site
Yantai, China

AstraZeneca Clinical Study Information Center

Research Site
Zhengzhou, China

AstraZeneca Clinical Study Information Center

Research Site
Naestved, Denmark

AstraZeneca Clinical Study Information Center

Research Site
Vejle, Denmark

AstraZeneca Clinical Study Information Center

Research Site
Dublin, Ireland

AstraZeneca Clinical Study Information Center

Research Site
Ancona, Italy

AstraZeneca Clinical Study Information Center

Research Site
Avellino, Italy

AstraZeneca Clinical Study Information Center

Research Site
Bologna, Italy

AstraZeneca Clinical Study Information Center

Research Site
Brescia, Italy

AstraZeneca Clinical Study Information Center

Research Site
Cagliari, Italy

AstraZeneca Clinical Study Information Center

Research Site
Catania, Italy

AstraZeneca Clinical Study Information Center

Research Site
Firenze, Italy

AstraZeneca Clinical Study Information Center

Research Site
Genova, Italy

AstraZeneca Clinical Study Information Center

Research Site
Livorno, Italy

AstraZeneca Clinical Study Information Center

Research Site
Milano, Italy

AstraZeneca Clinical Study Information Center

Research Site
Napoli, Italy

AstraZeneca Clinical Study Information Center

Research Site
Novara, Italy

AstraZeneca Clinical Study Information Center

Research Site
Palermo, Italy

AstraZeneca Clinical Study Information Center

Research Site
Perugia, Italy

AstraZeneca Clinical Study Information Center

Research Site
Reggio Emilia, Italy

AstraZeneca Clinical Study Information Center

Research Site
Verona, Italy

AstraZeneca Clinical Study Information Center

Research Site
Anyang, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Busan, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Cheongju-si, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Daegu, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Daejeon, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Gangwon-do, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Goyang-si, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Incheon, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Jeonju-si, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Jeonnam, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
JinJoo, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Seo-gu, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Seongnam-si, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Seoul, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Suwon-si, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Ulsan, Korea, Republic of

AstraZeneca Clinical Study Information Center

Research Site
Mexico, Mexico

AstraZeneca Clinical Study Information Center

Research Site
Querétaro, Mexico

AstraZeneca Clinical Study Information Center

Research Site
Dammam, Saudi Arabia

AstraZeneca Clinical Study Information Center

Research Site
Riyadh, Saudi Arabia

AstraZeneca Clinical Study Information Center

Research Site
A Coruña, Spain

AstraZeneca Clinical Study Information Center

Research Site
Alicante, Spain

AstraZeneca Clinical Study Information Center

Research Site
Badalona(Barcelona), Spain

AstraZeneca Clinical Study Information Center

Research Site
Barcelona, Spain

AstraZeneca Clinical Study Information Center

Research Site
Castellón, Spain

AstraZeneca Clinical Study Information Center

Research Site
Las Palmas de Gran Canaria, Spain

AstraZeneca Clinical Study Information Center

Research Site
Madrid, Spain

AstraZeneca Clinical Study Information Center

Research Site
Majadahonda, Spain

AstraZeneca Clinical Study Information Center

Research Site
Oviedo, Spain

AstraZeneca Clinical Study Information Center

Research Site
Palma de Mallorca, Spain

AstraZeneca Clinical Study Information Center

Research Site
San Sebastian, Spain

AstraZeneca Clinical Study Information Center

Research Site
Sevilla, Spain

AstraZeneca Clinical Study Information Center

Research Site
Valencia, Spain

AstraZeneca Clinical Study Information Center

Research Site
Zaragoza, Spain

AstraZeneca Clinical Study Information Center

Research Site
Orebro, Sweden

AstraZeneca Clinical Study Information Center

Research Site
Umeå, Sweden

AstraZeneca Clinical Study Information Center

Research Site
Uppsala, Sweden

AstraZeneca Clinical Study Information Center

Research Site
Bellinzona, Switzerland

AstraZeneca Clinical Study Information Center

Research Site
Bern, Switzerland

AstraZeneca Clinical Study Information Center

Research Site
Luzern, Switzerland

AstraZeneca Clinical Study Information Center

Research Site
St. Gallen, Switzerland

AstraZeneca Clinical Study Information Center

Research Site
Kaohsiung, Taiwan

AstraZeneca Clinical Study Information Center

Research Site
Taichung, Taiwan

AstraZeneca Clinical Study Information Center

Research Site
Tainan, Taiwan

AstraZeneca Clinical Study Information Center

Research Site
Taipei, Taiwan

AstraZeneca Clinical Study Information Center

Research Site
Taoyuan, Taiwan

AstraZeneca Clinical Study Information Center

Research Site
Al Ain, United Arab Emirates

AstraZeneca Clinical Study Information Center

Research Site
Aberdeen, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Antrim, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Leicester, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
London, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Newcastle-Under-Lyme, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Norwich, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Poole, United Kingdom

AstraZeneca Clinical Study Information Center

Research Site
Wolverhampton, United Kingdom